JAK inhibition in Down Syndrome Regression Disorder

Area of Science:

• Neuroimmunology
• Genetics
• Down Syndrome Research

Background:

• Down Syndrome Regression Disorder (DRSD) is a rare, severe condition in adolescents and young adults with Down syndrome (DS).
• Individuals with DS have immune dysregulation and increased autoimmune conditions, suggesting an immune basis for DRSD.
• Previous treatments, like intravenous immunoglobulin, show potential but are not universally effective.

Purpose of the Study:

• To investigate the efficacy of JAK inhibitors, specifically tofacitinib, in treating probable Down Syndrome Regression Disorder (DRSD).
• To describe the neurological and functional outcomes in individuals with DRSD treated with tofacitinib.

Main Methods:

• A case series approach was used, describing three individuals diagnosed with probable DRSD.
• The treatment administered was the JAK inhibitor tofacitinib.
• Outcomes were assessed across multiple domains of neurological function.

Main Results:

• All three individuals with probable DRSD showed improvement in symptoms after receiving tofacitinib.
• Improvements were observed across various domains of neurological function.
• Tofacitinib was generally well-tolerated in this small cohort.

Conclusions:

• JAK inhibitors, such as tofacitinib, represent a potential novel therapeutic strategy for Down Syndrome Regression Disorder (DRSD).
• Further research, including larger clinical trials, is warranted to confirm the efficacy and safety of tofacitinib for DRSD.
• Targeting immune dysregulation may be a promising avenue for managing DRSD in individuals with Down syndrome (DS).